Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezuclastinib in Advanced Systemic Mastocytosis
NCT04996875Phase 2Recruiting
- Sponsor
- Cogent Biosciences
- Start
- Nov 2021
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 14
01
Overview
A Phase 2 trial of bezuclastinib in systemic mastocytosis (SM), sponsored by Cogent Biosciences. Started Nov 2021; status: recruiting.
02
Drugs
bezuclastinib
03
Conditions
systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT04996875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996875.